Skip to main content
. 2022 Feb 25;6(5):1394–1405. doi: 10.1182/bloodadvances.2021004934

Figure 5.

Figure 5.

OS according to IDH2 mutational status in ELN 2017 intermediate- and adverse-risk patients. Kaplan-Meier plots for OS of patients with AML within the ELN 2017 intermediate- and adverse-risk group in regard to mutated IDH2-R140 (blue), mutated IDH2-R172 (green), and WT IDH (orange); time in months.